Ravulizumab Study in Chinese Adults with Generalized Myasthenia Gravis Initiated by Alexion
A clinical trial is underway to assess the efficacy and safety of ravulizumab in Chinese adults with generalized myasthenia gravis.
Therapeutic Area
Therapeutic area intelligence for Myasthenia Gravis with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has accepted a supplemental NDA for Pyridostigmine Bromide submitted by Amneal.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.